# PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

> **NCT03897491** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **photonamic GmbH & Co. KG** · enrollment: 20 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** 5-aminolevulinic acid

## Key facts

- **NCT ID:** NCT03897491
- **Lead sponsor:** photonamic GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-03
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03897491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03897491, "PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03897491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*